Peptide Therapeutics' Rising Tide
This article was originally published in Start Up
Executive Summary
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.
You may also be interested in...
Bicycle Therapeutics Ltd.
Natural peptides have plenty of drawbacks that have held them back when it comes to pharmaceutical applications: their highly unstable amino acid chains degrade too quickly to produce a therapeutic effect, discovery has been difficult to industrialize, and manufacturing complex and costly. However, emerging technologies for synthetically stabilizing peptide structures may eventually conquer most of natural peptides’ drawbacks as pharmaceuticals. Bicycle Therapeutics Ltd. hopes its two-wheel “constrained” peptides it calls “bicycles” will ride off with the prize for exploiting nature’s medicines.
Aileron Overcoming Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
With Dueling Papers Comes A Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.